1. Home
  2. BIRD vs VTGN Comparison

BIRD vs VTGN Comparison

Compare BIRD & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Allbirds Inc.

BIRD

Allbirds Inc.

HOLD

Current Price

$2.49

Market Cap

26.2M

ML Signal

HOLD

Logo VistaGen Therapeutics Inc.

VTGN

VistaGen Therapeutics Inc.

HOLD

Current Price

$0.27

Market Cap

25.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BIRD
VTGN
Founded
2015
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Apparel
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
26.2M
25.3M
IPO Year
2021
2014

Fundamental Metrics

Financial Performance
Metric
BIRD
VTGN
Price
$2.49
$0.27
Analyst Decision
Hold
Hold
Analyst Count
1
3
Target Price
$8.00
$0.90
AVG Volume (30 Days)
304.0K
2.8M
Earning Date
05-07-2026
06-16-2026
Dividend Yield
N/A
N/A
EPS Growth
20.22
N/A
EPS
N/A
N/A
Revenue
$152,466,000.00
N/A
Revenue This Year
N/A
$124.49
Revenue Next Year
$35.12
$353.99
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.15
$0.20
52 Week High
$24.31
$5.14

Technical Indicators

Market Signals
Indicator
BIRD
VTGN
Relative Strength Index (RSI) 38.80 42.81
Support Level $2.45 $0.21
Resistance Level $3.36 $0.66
Average True Range (ATR) 0.16 0.02
MACD 0.07 0.02
Stochastic Oscillator 42.25 48.54

Price Performance

Historical Comparison
BIRD
VTGN

About BIRD Allbirds Inc.

Allbirds Inc is a lifestyle brand that innovates with naturally derived materials to make footwear and apparel products in a better way, while treading lighter on the planet. Its primary source of revenue is from sales of shoes and apparel products. The majority of the revenue is derived from United States.

About VTGN VistaGen Therapeutics Inc.

Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.

Share on Social Networks: